These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24663031)

  • 1. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 2. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
    Monaco TJ; Davila CD
    Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit
    Takahashi S; Horie R; Yokoyama Y
    Nihon Yakurigaku Zasshi; 2017; 149(1):49-58. PubMed ID: 28049880
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
    J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil (Adcirca) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):87-8. PubMed ID: 19890245
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Lefebvre MC; Hunsche E
    Appl Health Econ Health Policy; 2010; 8(1):69-71; author reply 71-3. PubMed ID: 20238466
    [No Abstract]   [Full Text] [Related]  

  • 12. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 14. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan.
    Tynan T; Hird K; Hannon T; Gabbay E
    J Int Med Res; 2019 May; 47(5):2177-2186. PubMed ID: 30975046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Opsumit for pulmonary hypertension].
    Sabourin G
    Perspect Infirm; 2014; 11(4):56. PubMed ID: 25269244
    [No Abstract]   [Full Text] [Related]  

  • 16. Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension.
    Maeder MT; Kleiner R; Weilenmann D
    Int J Cardiol; 2016 Jan; 202():244-5. PubMed ID: 26402452
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
    MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
    [No Abstract]   [Full Text] [Related]  

  • 20. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.